Cargando…
Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy
The immune-excluded tumors (IETs) show limited response to current immunotherapy due to intrinsic and adaptive immune resistance. In this study, it is identified that inhibition of transforming growth factor-β (TGF-β) receptor 1 can relieve tumor fibrosis, thus facilitating the recruitment of tumor-...
Autores principales: | Zhou, Mengxue, Wang, Jiaxin, Pan, Jiaxing, Wang, Hui, Huang, Lujia, Hou, Bo, Lai, Yi, Wang, Fengyang, Guan, Qingxiang, Wang, Feng, Xu, Zhiai, Yu, Haijun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275881/ https://www.ncbi.nlm.nih.gov/pubmed/37328484 http://dx.doi.org/10.1038/s41467-023-39035-x |
Ejemplares similares
-
Self‐Cooperative Prodrug Nanovesicles Migrate Immune Evasion to Potentiate Chemoradiotherapy in Head and Neck Cancer
por: Zhu, Yun, et al.
Publicado: (2022) -
Extracellular vesicles hybrid plasmid-loaded lipid nanovesicles for synergistic cancer immunotherapy
por: Tong, Qing, et al.
Publicado: (2023) -
Application of lipid nanovesicle drug delivery system in cancer immunotherapy
por: Ding, Yinan, et al.
Publicado: (2022) -
Genetically Engineered‐Cell‐Membrane Nanovesicles for Cancer Immunotherapy
por: Cheng, Qinzhen, et al.
Publicado: (2023) -
Design of an activatable NIR-II nanoprobe for the in vivo elucidation of Alzheimer's disease-related variations in methylglyoxal concentrations
por: Lai, Yi, et al.
Publicado: (2022)